Come and talk to us at the UK Pavilion (765) about how we can help support your research and development requirements with consultancy and assay development from our world-renowned experts, our wide range of specialist services and diagnostics, our high containment facilities and our ability to provide high throughput laboratory analysis capacity. The UK Health Security Agency (UKHSA) is responsible for planning, preventing and responding to external health threats, and providing intellectual, scientific and operational leadership at national and local level, as well as globally. We are an executive agency, sponsored by the Department of Health and Social Care. The Agency operates a network of laboratories across England including centres of excellence at Colindale (London) and Porton (Wiltshire), providing a range of clinical, reference and public health microbiology services including bacteriology, mycology, virology, immunology, and genomics. Leadership in communicable diseases, field epidemiology and rapid investigations is also supported by real-time surveillance and analysis and emergency preparedness and response activities delivered via regional health protection teams. All our laboratories have active research and development interests, including the evaluation of novel vaccines, antimicrobials, and in vitro diagnostics, and all our clinical laboratories can assist with access to clinical samples, including novel and emerging pathogens. Our key services include conducting 4 million regional laboratory tests, analysing 350,000+ reference samples, performing 190,000 genomic sequences annually, handling 40,000 rare pathogen referrals, and processing 500,000 radiation dosimeters yearly. We also offer advanced diagnostic capabilities, world-leading expertise in vaccine evaluation and phage translation/application, and have one of the strongest behavioural science units in UK Government. We employ 3,000 scientists across 30+ disciplines and we maintain strong partnerships with 500+ universities globally. Our intellectual property portfolio includes 165 patents and 64 trademarks. UKHSA’s unique position as a public health organisation combines scientific expertise, laboratory infrastructure, and research capabilities. Our income generated from commercial services strengthens our core health security work, while our collaborative approach with industry and academia drives public health benefits and economic growth. We provide a comprehensive range of specialist health security services and products, addressing challenges in public health protection and disease surveillance. These consist of a range of clinical, reference and public health microbiology services including bacteriology, mycology, virology, immunology, and genomics. Leadership in communicable diseases, field epidemiology and rapid investigations is also supported by real-time surveillance and analysis and emergency preparedness and response activities delivered via regional health protection teams. Our key services include: Radiation personal dosimetry service (processing ~500,000 dosimeters annually) Regional laboratory testing (4 million tests supporting NHS diagnostics and public health outbreaks) Reference services (350,000+ samples for specific pathogen analysis) Genomic sequencing (90,000 next-generation and 100,000 Sanger sequencing samples annually) Rare and Imported Pathogen Laboratory services (40,000 NHS referrals) UKHSA’s competitive advantages include: One of the strongest behavioural science and insights functions in UK Government Employment of 3,000 scientists across 30+ scientific disciplines Extensive intellectual property portfolio (165 patents and 64 registered trademarks) Strong partnerships with academia (500+ universities globally) Advanced diagnostic capabilities and accelerator programme World-leading expertise in phage translation and application High containment facilities for in vivo and in vitro research (BSL 3 and 4) Our value proposition lies in our unique position as a public health organisation combining scientific expertise, extensive laboratory infrastructure, and research capabilities. The income generated from commercial services strengthens our core health security services, while our collaborative approach with industry and academia drives both public health benefits and economic growth.
TubeWriter
TubeWriter labeling systems is a full-feature instrument for printing directly at high-speed on the sides and caps of plastic, glass, and curved surfaces, including tubes, vials, slides, plates and custom labware. It is designed to address automating laboratory printing for assays, protocols and experiments. TubeWriter labeling withstands the harshest of lab conditions; resistant to chemical solvents and surviving long-term storage at -80C and liquid nitrogen. | TubeWriter is an automated labeling systems that prints directly on the surface of any labware eliminating the need for sticky labels. For laboratories that perform medium to high-throughput applications struggling with manual labeling or paper labels, the TubeWriter prints directly on the sides and caps of tubes, vials, plates and unique labware. TubeWriter prints text, images, and barcodes using UV-curable ink that withstands extreme lab conditions, most harsh chemicals and long-term storage at -80C and liquid nitrogen.
TrialAssure
TrialAssure® delivers AI Enabled, Human Driven™ solutions for data, document, and image anonymization, medical writing, and clinical trial transparency. With this approach, we help life sciences be efficient, enhance disclosure, and protect patient privacy. Please reach out if you are looking for an AI-enablement partner.
Trace Biosciences
Trace Biosciences is creating imaging agents for surgery. Our mission is to revolutionize surgery by highlighting detailed anatomy in real-time. Our first product is a nerve targeting imaging agent that will prevent surgical nerve damage. Nerve injury is a feared surgical complication affecting 25 million patients annually and incurring undue pain, loss of function, and high cost for follow on treatment and pain management. Currently, surgeons are entirely unassisted in nerve identification and preservation, relying solely on naked eye visualization or anatomical knowledge. If we can successfully develop this, our imaging agents will be used in almost all operating theaters, enable true precision surgery, and vastly improve patient outcomes. We are well funded through non-dilutive grants (SBIR, STTR + regional government) as well as venture capital investments.
TLC BioSciences
TLC BioSciences is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD®). TLC’s deep experience with liposome science allows TLC to combine onset speed and benefit duration, and improve active drug concentrations while decreasing unwanted systemic exposures. TLC’s BioSeizer® technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX® active drug loading technology is designed to alter the systemic exposure of the drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology. TLC was consistently ranked in the top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations every year until the company went private in 2021. | TLC BioSciences is a late clinical stage specialty pharmaceutical company. At TLC, we are dedicated to the research, development, and commercialization of novel nanomedicines that maximize the potential of our proprietary lipid-assembled drug delivery platforms (LipAD®). With three approved drugs in our track record, our expertise in liposome science allows for a combination of rapid onset and extended benefit duration, enhancing active drug concentrations while minimizing systemic exposures. Our BioSeizer® technology enables local sustained release of therapeutic agents at the site of disease or injury. Our NanoX® active drug loading technology alters systemic exposure and potentially reduces dosing frequency. Our new early-stage assets include gene therapy and lipid nanoparticle (LNP) treatments with the potential to regenerate cells. Versatile in active pharmaceutical ingredients and scalable in manufacturing, these technologies address unmet medical needs in orthopedics and pain management. | TLC is dedicated to the research, development, and commercialization of novel nanomedicines that maximize the potential of our proprietary lipid-assembled drug delivery platforms (LipAD®). With three approved drugs in our track record, our expertise in liposome science allows for a combination of rapid onset and extended benefit duration, enhancing active drug concentrations while minimizing systemic exposures. Our BioSeizer® technology enables local sustained release of therapeutic agents at the site of disease or injury. Our NanoX® active drug loading technology alters systemic exposure and potentially reduces dosing frequency. Our new early-stage assets include gene therapy and lipid nanoparticle (LNP) treatments with the potential to regenerate cells. Versatile in active pharmaceutical ingredients and scalable in manufacturing, these technologies address unmet medical needs in orthopedics and pain management. | TLC BioSciences is a clinical‑stage biotechnology company advancing lipid‑engineered medicines across metabolic, orthopedic, and immune‑cell therapy. Our proprietary LipAD® family of platforms—including BioSeizer® sustained‑release technology, NanoX® active drug‑loading systems, and next‑generation targeted lipid nanoparticles (tLNP)—enables long‑acting, targeted, and programmable delivery for a wide range of therapeutic modalities. With a robust pipeline spanning once‑monthly GLP‑1 therapy (TLC518), late‑stage non‑opioid pain programs, and in‑vivo CAR‑T applications, TLC is committed to delivering medicines with improved efficacy, safety, and accessibility.
TJOAPACK
Tjoapack is a leading global pharmaceutical contract packaging solutions provider that operates production facilities in Europe and the US. Our extensive services cover primary packaging for oral solids, such as blister packs and bottles, as well as secondary packaging in all formats. We also specialise in custom packaging solutions for vials and pre-filled syringes. Furthermore, our services include customised kit assembly, serialisation and aggregation, product market release, clinical trial packaging, packaging for narcotic substances, re-packaging, and logistics management, along with analytical testing.
Tigermed
Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 2,800 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across Asia Pacific, Europe, North America, Latin America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients’ needs, and ultimately saving lives. | Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are committed to moving our customers through their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 100 subsidiaries and 180 service locations, with over 10,000 employees across 54 countries in Asia Pacific, Europe, North & South America and Africa. We are devoted to building an integrated platform that enables boundless possibility for healthcare industry, embracing challenges to fulfill our commitment to serve unmet patients’ needs, and eventually saving lives. | Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 3,200 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across Asia Pacific, Europe, North America, Latin America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients’ needs, and ultimately saving lives.
tcmc (Taiwan Cell Manufacturing Company)
At tcmc, we specialize in delivering premium-quality lentiviral vectors (LVVs) and cell therapy products tailored to meet your needs. LVVs play an important role in genetic engineering of T cells, and we offer advanced solutions for LVV manufacturing to support gene-editing T cells, from R&D to full-scale commercialization. But that’s not all—our expertise extends to the manufacturing of non-genetically modified cells as well, including Dendritic Cells (DC), Natural Killer cells (NK) and stem cells. Furthermore, we understand the complex world of compliance, so every CDMO service we provide is accompanied by robust regulatory support for your CMC package. From groundbreaking research to life-changing therapies, tcmc is your trusted partner in developing next generation therapies. Let’s advance the future of healthcare together. -Taiwan Cell Manufacturing Company
Taiwan Pavilion
Taiwan is located in the center of the Asia-Pacific region, with abundant medical resources, and diverse clusters of information and communication, semiconductor, and biomedical industries. It is suitable for the investment in development of precision health industries such as high-end medical materials, AI computing, and big data analysis. Taiwan medical device manufacturers have developed actively medical research and technology and we hope to cooperate with local industries, so it will be easier to enter the supply chain of major international brands. Metal Industries Research & Development Centre (MIRDC), a non-profit organization from Taiwan and assists Taiwan government to cultivate and reinforce the medical device industry in Taiwan. We also develop medical device products and technologies in industries including dental and orthopedic implants, devices, medical imaging, minimally invasive surgery instrument, and healthcare. | The biomedical industry is one of the six core strategic industries in Taiwan. It is an important power for Taiwan to play the leading role in global economy. With rich experiences of research, development and manufacturing, Taiwan excels in high-tech fields, clinical trials and biologics production. Continuing R&D support from government has created highly skilled workforce to innovate and advance the industry. Besides, Taiwan’s strategic location and grown-up supply chain make it an ideal partner for worldwide collaboration. There are more than 60 exhibitors and institutions in the Taiwan Pavilion this year, covering new drug development, CRO, CDMO, agriculture biotechnology, medical devices, precision medicine and smart health fields. Come and Join us to shape the future of precision health for all ages through collaboration and innovation with Taiwan’s thriving biomedical industry! | The biomedical industry is an important power for Taiwan to play the leading role in global economy. With rich experiences of research, development and manufacturing, Taiwan excels in high-tech fields, clinical trials and biologics production. Continuing R&D support from government has created highly skilled workforce to innovate and advance the industry. Besides, Taiwan’s strategic location and grown-up supply chain make it an ideal partner for worldwide collaboration. There are more than 60 exhibitors and institutions in the Taiwan Pavilion this year, covering new drug development, CRO, CDMO, agriculture biotechnology, medical devices, precision medicine and smart health fields. Come and Join us to shape the future of precision health for all ages through collaboration and innovation with Taiwan’s thriving biomedical industry! | BPIPO is honored to lead Taiwan’s delegation, featuring around 40 prominent companies and organizations specializing in new drug development, CDMO, regenerative medicine, agricultural biotechnology, precision medicine, and smart health. We warmly invite you to visit the Taiwan Pavilion and explore opportunities for collaboration. At our pavilion, you’ll discover not only innovative business partnerships but also insights into Taiwan’s supportive biomedical policies and unique research ecosystem. Taiwan has dedicated decades of effort to fostering a thriving biomedical industry, supported jointly by government initiatives and private sector innovation. This collaborative environment has successfully driven cross-domain growth and positioned Taiwan as a global biotechnology hub.